5.
Question 5
Increased in interest in pharmacoeconomic data was described as coming from where?
1 point
pharmaceutical companies wanting to build better models to guide drug development
the FDA looking to prioritize future application processing
insurance companies wanting to determine if there would be a cheaper standard of care
